Torben Elm

Senior Scientist
Novo Nordisk

Presentation(s):

• OC 78.3 - HMB-001 – a novel bispecific antibody accumulating and targeting endogenous FVIIa to activated platelets for subcutaneous prophylaxis in multiple bleeding disorders including Glanzmann Thrombasthenia

  Wednesday, July 13, 2022
  10:45 AM – 11:00 AM